Testing effectiveness (Phase 2)Study completedNCT05630066
What this trial is testing
Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
Who this might be right for
Angelman Syndrome
Hoffmann-La Roche 48